assumptions that could cause actual results to differ
materially from estimates or projections in the forward-looking statement
include, but are not limited to: (i) the risk that molecular testing
methods will not penetrate the food testing market, (ii) the risk that
development efforts for MRSA or other projects may not be timely or
successful, (iii) the possibility that new products will not be competitive
or gain market acceptance, and (iv) the risk that collaborations cannot be
maintained. For additional information about risks and uncertainties we
face and a discussion of our financial statements and footnotes, see
documents we have filed with the SEC, including our Report on Form 10-K for
the fiscal year ended December 31, 2006 and all our periodic filings made
with the SEC. We assume no obligation and expressly disclaim any duty to
update any forward-looking statement to reflect events or circumstances
after the date of this news release or to reflect the occurrence of
subsequent events.
Contact:
Michael Watts
Sr. director, investor relations and corporate communications
858-410-8673
'/>"/>SOURCE Gen-Probe Incorporated Copyright©2007 PR Newswire. All rights reserved | |
Page: 1 2 3 Related medicine news :1.
A new molecular zip code, and a new drug target for Huntingtons disease2.
New knock-out gene model provides molecular clues to breast cancer3.
Molecular probe paints cancer cells in living animals, Stanford researchers find4.
Story ideas from molecular & cellular proteomics5.
SNM seeks novel approaches to molecular imaging to showcase at annual meeting6.
SNM seeks novel approaches to molecular imaging to showcase at annual meeting7.
Molecular fingerprint of breast-cancer drug resistance can predict response to treatment8.
Molecular profiling can accurately predict survival in colon cancer patients9.
Xceed Molecular Names Fran Tuttle to Its Board of Trustees10.
Virginia G. Piper Charitable Trust and Flinn Foundation launch molecular diagnostics initiative11.
Xceed Molecular Launches Ziplex(R) Automated Gene-Expression System at the Association for Molecular Pathology, Booth 84/85